Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy  by Kirshenbaum, James M. et al.
REPORTS ON THEKAPY 
JAMES M. MIRSHENBAUM. MD. FACC. ROl3iZKT F. KLONER. MD. PHD. FACC.* 
NOREEN MCGOWAN, RN, ELLIOTT M. ANT?n.AN. MD. FhCC 
Boston. M”ssork,,serrr 
Many clinical and experimental studies (I.21 have demon- 
strated that beta-adrenoceptor blocking agenls are beneficial 
during myucardial irchemla. The use of Bela-b!uckerc 5oon 
after ibe onset of chest pain III patlen!s with suspected acute 
myocanllal infarction or unstable angina is &clive to 
reducing the risk of progression 10 infarction or cmfaraion 
13.41: uragc is effective as well in reduwg the mcldence of 
venwiculsr fibrillation and total card& mortality during the 
initial phae of hospitabzation for myocardial iniarction 
I5.61. Review ofbeta-biurtade trials in myocardial infarction 
17.81 ah wggcst~ that early trealment may reduce infarct 
we hy I5 10 2070. 
In carefully screened patients airh acute tschemia. the 
rlrk of inmatmg or exacerbating congestive heart fadure. 
hypotemion. bradycardn. hcan block or bronchospasm 
wth mtraveoous beta-blockers is eenerally 62 I’%II). 
most hkcly to hcnefit from ruch lhelapy (12). In recent 
randomircd clinical trials (I?-151. nearly a quarter of pa- 
ticttts wth caiiy infxclion initially screened for cnrollmcnt 
were excluded from participation because of the presence of 
on ahso!:ite or relatwc contraindication to beta-blockade. 
Esmolol. a recently relexed ultrashort-acting cardiore- 
l~ctwe beta-blocker, may prove useful I” this setting because 
its rhon binlogw half-life (trp = 9 min) would allow both 
rapid titration to a specific hemodynamtc target and rapid 
reversal of drug effect shoold any untoward reacdon occur 
(16). Ecmolol has heen used in clinical studies 117-23) that 
have confirmed its safety and eiiicacy in the treatment of 
rupmvcntricolar arrhythmias and in the management of 
txhycardia or hypertension associated with anesthesia in- 
duction. tracheal intubntion or the postoperative period. In 
animal studies. e\moiol appeared to reduce ischemic myo- 
cardial damage (24): it \L~P effective in lowering the heat 
rate and blood pressure in patients with myocardial infarc- 
tion or unstable angina (25). The clinical use of a titmtable 
beta-blocker would broaden the potential application of 
intravenous hcta-blockade in the settin& of acute ischcmic 
heart dixxc to include patients with relative contraindica- 
tions lo beta-blockade therapy. 
Therefore. the purpose of this investigation was twofold: 
I) to study the pharmacodynamic profile of esmolol in 
patients with acote ischemia and compromised left ventric- 
ulilr function. and ?I to assess the safety of “cute intravenous 
beta-blockade with an ultrashart-acting agent in patients 
with a relatwe contraindicai”” to hcta-blocker treatment. 
Methods 
Study patients. We pnviously reported (25) the hemody- 
namic effects of shon-term use of esmclol in 19 patients with 
acute myocardml ischema Esmolol produced an easily 
titratahlc reduction m heart rate. blood pressure and cardiac 
output withok L any appreciable effect on putmo”ary cap,,.. 
lary wedge pressorc or PR interval. To determine if patients 
with relative hemodynamic contraindications to beta- 
blockade had a less favorable response to esmolot. we 
stodxd an additional IO patients with acute myocardial 
inf%ctmn or unstable angana acsocnted with compromised 
left ventricular function a cvidcnced by a” elevated mean 
pulmonary capillary wedge pressure. The present report 
details the hemodynamlc response in these 10 patients plus B 
wbsct of 6 patienta from our prior reoort (25) who had 
simdar degreEa of compromised left ventricular function. 
Sixteen patients (6 men and IO women). aged 65 2 II 
(mean + SD) years. with” mean pulmonary capillary wedEe 
pressure of 15 to 25 mm Hg and thus considered to have a 
relative contraindication to beta-blockade were enrolled. All 
patients had active iachems heart disease. Nine natients 
witbout ongoing active ischemia were studied between 4 and 
24 h after onset of acute myocardiat infarction; six were 
treated because of nogina at rest “ccurrmg >24 h hot <I 
week after myocardial infarction. and one received therapy 
for acute unstable angina without rvidence for recent infarc- 
tion. All patients had sinus rhythm with a ventricular rate 
>75 beatslmin before the esmolol infusion, which WBS car- 
ried out in the coronary care “no of Brigham and Women’s 
Hospital. 
Acute myocardial infarction was diagnosed by a history 
of typical chest pain lasting ~30 min. a” increase in total 
serum creatine kinase (CK) above the normal raw associ- 
ated with the presence of the myocardial-specific isoenzyme 
MB CK at twice the normal ratwe and evolutiomw ST-T 
wave and QRS criteria for myoca~dial infarction in&ding R 
wave loss and development of pathologic Q waves. Unstable 
angina was characterized by iechemic chest pain occurring at 
rest. accompanied by transient electrocardiographic (ECG) 
changes of ST segment elevation or depression or T wave 
flattening or inversion. Any such episodes in which ECG 
changes and ischemic pain occurred in the absence of serum 
CK elevation >24 h after acute infarction were also consid- 
cred indications of unstable angina. 
Pariem II~~ excluded if they had systolic blood pressure 
<I IO mm Hg before therapy. second or third degree atrio- 
ventricular (AV) block. new bilateral bundle branch block or 
trifasciculsr block. a prior history of bronchospasm or 
severe chronic obstructive pulmonary disease, cardiogenic 
shock or pulmonary capillary wedge pressure >25 mm Hg, 
severely impaired renal or hepatic function or significant 
cardiac valvolar disease or treatment with a beta-blocker 
within k2 excretory half-lives before trial entry. All patients 
who participated gave written informed consent. and the 
study protocol was approved by the Human Subjects Com- 
mittee of the Brigham and Women’s Hospital. After consent 
was obtained, a 24 h ECG monitor was applied and baseline 
hemodynamics were determined immediately before initia- 
tion of the esmotot infusion. 
Trealment protocol. Pulmonary artery balloon Rotation 
catheters were inserted in all 16 patients. A IO me/ml 
solution of esmolol (Brevihtoc, D&t Critical Care) was 
infused with an IMED model 9X volumetnc “urn” into a 
periphenl vein in each patient. The drug was admioistered 
over a 35 min titration period r:onsisting of up to seven 
consecutive 5 min infusion periods. Each inhrion period 
consisted of a 500 &kg body weight per mitt loading dose 
for 30 s followed by a 4.5 mitt infusion of 25, then 50 &kg 
per min of esmolol. The loading dose was then increased to 
500 we/kg PT min for I otin followed bv 4 min infusions of ._ _. 
100. 150. 200. 250 and 300 &kg per I& of esmolot. This 
regimen was followed until cithcr the peak dose of 300 pg/kg 
per min had been given, the rate-pressure product decreased 
hy >30% or systolic pressure decreased to <9il mm He or if 
hronchospasm. cardiogenic shock. heart rate ~60 beats/mitt 
or second degree or greater bean block developed. If nec- 
pulmonary artery pressure and the mean presrure m the 
pulmonary capdlary wedge pocitmn were wmlarly maw 
tored. Cardiac index was determinsd at basclme. after the 
titration p?ricd. at the end of the mamtcnance period md 30 
min after termination of the infusiun by the rhermudiluuon 
method with an Instrumentation Laboratone, model 701 
cardiac output computer (mean of 3 to 5 measuremems). 
The design of this study did not include monitoring of ST 
segments for evidence of silent i&hernia but rather focused 
an symptomatic episodes of ischemin for which ECGI were 
obtained as clinically indicated. All patients were continu- 
ously monitored for evidence of cardiac arrhythmrae by way 
of hardwire ECG bedside monitorr. Physical examinatmn 
and standard laboratory tests (urinaiysis. complete biood 
count and chemistrv values) were performed bcforc and 
after the esmolol in&on. 
Mean arterial pressure ,mm Hz) was calculated OF (2 x 
diastolic + systolic pressure~:3. aid the rate-pressure prod- 
uct WBE defined as systolic blood prerwre x heart rate. 
Sb~tistical analysis. Data were analyzed by 8 repeated 
measures analysis of variance. Results are prexnted as 
mean values f I SD and differences were considered statis- 
tically significant at the p 5 0.05 level. 
Results 
EUecb of esmolol on heart rate, bload Pressure and rate. 
pressure product (Table I). Esmulul rapidly produced a 
sienificant reduction m sinus rate without the develooment 
ofclinically significant prolongation ofAV conductionin any 
patient (the PR interval was 0. I7 ? 0.03 I at baseline and was 
0.17 + 0.03 s at the end of the maintenance infusion, p = 
NS). The mean baseline sinus rate of 99 ? I2 beats/mm 
(range 79 to 118) decreased to 87 + I3 beatnlmin within IO 
min of starting the infusion at a dose of50 &kg per mm and 
to a nadir of 80 f I4 beatrimin (p 5 0.05 versus baseline) 
during the maintenance phase (Fig. IL Further augmentation 
of the esmolol infusion resulted in only a modest additional 
reduction in sinus rate with most patients achieving the 
maximal decrease in sinus rate at a dose of 100 to 200 &kg 
per min. There was no stgniticant change in the sinus mte 
during the maintenance phase. Within IS min of stopping the 
infusion there was a rapid increase in sinus rate and vxtually 
complete resolution of drug effect occurred uithm approx~- 
mately 30 mm. 
The ,rrrrmL arkrid prewtre responded rimilarly wth d 
decline from 126 ? I9171 5 12 189 2 Ill mm Hg Isys!olicl 
diawhc Imeant]) at hawline to 107 + 20162 r 8 178 2 IOI mm 
Ilg at the end of the maintenance phaw As compared with 
bawlinc values these rewlts represented a 15% decrsasc in 
systolic. 13% decrease in diastolic and a I?% decrease tn 
mean pre\wres. There was no significant change in blood 
pressure during the maintenance phase, and within 30 min 
after termination of the infusion the arterial pressure re- 
turned 80 I24 + 22ibY f 9 187 t IO] mm Hg (p = NS verws 
haselinc) (Fig. 2). Unlike the heart rate response. there 
appeared to be a persistent duse-dependent elfect of e~mulol 
on mtencd pressure with a continuing decline in pressure as 
the dose was increased. 
The decline in arterial pressure and heart rate re,ult;d in 
a dechne in rate-pressure product of 33% by the end of the 
maintenance phase achieved at a mean dose of 172 + 80 pg! 
kg per min. Thirty minutes after the esmolol infusion was 
stopped the mean rate-pressure product returned to ~9% of 
the baseline values. 
Effec& of esntolol on pulmonary capillary wedge and 
cardiac index(Tabie Il. Pulmonary capillary wedge pressure 
was not significantly altered during the esmolol infusion 119 
r 3 mm Hg [baseline] versus 19 ? 5 mm Hg lend- 
maintenance], p = NSI, whereas the cardiac index declined 
approximately 14% (2.9 -C 0.7 to 2.5 -C 0.8. p = NS) by the 
end of the maintenance period and no clinical congestive 
heart failure occurred (Fig. 3). Even in patients who required 
early termination of the esmolol infusion because of oliguria 
or hypotenaton (see next paragraph). there was no nignificanl 
change in pulmonary capillary wedge pressure. 
Adverse re%ctiotw during ermolol infusion. Nine of the 16 
patients were additionally receiving intravenous nitroglyc- 
erin at the start of the esmolol infur;on and 4 requnred 
(ry,pmin, 
Figure 1. A. Individua! rcrponser in heart rate IHRI during Inc 
titmlion and .wwery phases of esmolol infusion. B. Mean heart 
rate (*SD) in all 16 patients during rhe fitradon. maintenance and 
recovery phascr. Recovery values for Pauent 16 are not included 
because lhir patient required a-hort-term dopamine infusion during 
data collection ia the re:over/ phase. 
titration downward of the nitroglycerin infusion rate tu 
prevent a decline in arterial pressure 40 mm Hg systolic. 
One of these four patients developed recunent angina thal 
required resumption of inlravenous nitroglycerin and subse- 
quenl discantinuatina PI esmolol 10 maintain lhe systolic 
pressure 30 mm fig. None of the other patients who 
underwent downward titration of naroglycerin infusion de- 
velo?ed clinical ischemic symplomr. 
Two patients. bath receiving intravenous nitroglycerin, 
underwent downward titrlion of the esmolol mainxnance 
infusion rate (from 300 10 200 and from 300 to IS0 i&kg per 
Figure 2. A. Individual responses in systolic hlwd pressure (BP1 
during the tilmtion and recovery phases ofthe emolol infusion. B, 
Systolic and diastolic @wan f SD) arterial pressure in all 16 patienta 
during the tifretinn. maintenance and recovery phases. Recovery 
values for Patienl I6 are na inchded because this patient rtquired 
a short dopamine infusion during data collection in the recovery 
phase. 
min. respectively) because they had a reduction in vstolic 
an&4 pressure 10 490 mm Hg although they were arym~- 
tomulic. In both patients a reduction in the infusion rate 
resulted in a return of systolic pressure tu 30 mm Hg. 
Four patients, one af whom was receiving intravenous 
nitroglycerin at 200 to 5W timin, required termination af 
the esmulol infusion because of either oliguria (one patient) 
or continued systolic hypotenrion (three patients) (Fig. 4). 
The firs1 patient was an 82 year old man with persistent 
angina at rest after a non-Q wave myucardial infurction. His 
Figure 3. A! Mean pulmonary capillary wedge pressure PC?!I) and 
B, cardiac mdex in all I6 patients at baseline. end of mamtenance 
infusion and 30 min after terminadon ofesmulol infunon. 
heart rate at rest and blood pressure declined from 103 bears/ 
min and 158/81 mm Hg to a nadir of 69 beatsimin and I l2I72 
mm Hg after a 5 h infusion of esmolol. This result was 
associated with a >50% decrease in rate-pressure product. a 
decline in cardiac index from 2.5 to I .5 liters/m/n per m’ and 
no change in pulmonary capillary wedge pressure. Becawe 
wine output declined to <IO mlih. the esmolol infusion was 
discontinued. Thirty minutes later the heart rate was 90 
beats/min, blood pressure 118/74 mm Hg and urine output 
returned to >30 to 50 ml/h. The other three patients all 
received esmolol within 24 h of an acute infarction and 
trr&ient hypotension developed as a direct drug effect in 
one, during an acute vagal episode in the second and during 
a lteufleni iscbemic episode in the third. Discontinuation of 
esmolol administration resolved the hypotension in the first 
two patients, wherear i Srief infusion of dopamine was 
necesrary in the third, whose blood pressure recoverrd 
within 20 ruin of discontinuation of esmolol infusion. The 
time course for recovery of kcart rate and arterial pressure in 
these three patients is depicted in Figure 4. 
Despite rke relorive conrraindicalions ro beta-blockers in 
rke p&wrs studied, rkere were no episodes ofiniriorion or 
exacerborion of overr congestive hrarf failure 01 clinically 
symptomatic kyporension or bmdycardia. Rouline blood, 
Figun4. A, Heart rate response inthree patienls with compromsed 
left ventncular function and a hypotensive or oliguric reaction. The 
hcan me returned IO baseline values in all three patients within 30 
min of termination ofesmolol infusion. E. Systolic anzrial pressure 
response mthe same three pgtienln. Blood prewre rctwned toward 
baseline values within 30 min after terminalion cl the infusion. One 
patient (data not shown) rcquicd a brief infusion of *pamine to 
reerrablish baseline arterial prwure. 
urinary and ECG studies showed no significant alteration 
during the infusion. As mentioned previously. drwinduced 
de&es in systolic pressure rapiey and reliably resolved 
after termination of the esmolol infusion when the systolic 
blood f~ressure decreased to <90 mm H& 
MSCWSiOR 
Rationale for beta-blockade in myorardill isckemia. Beta- 
adrenaceptor blocking agents are freqvently used in the 
contemporary management of patients with an acute ische- 
mic syndrome because they reduce myocardial oxygen de- 
mand by lowering hean rare. arterial pressure and myoc‘ar- 
dial contractility. Several studies (26) have demonstrated 
lhezr efficacy in diminishing the frequency of angina, raising 
the anginal threshold. aborting threatened myocardial infarc- 
tion and reducing mortality or the incidence of reinfarction in 
patients surviving myocardial infarction. Clinical studies with esmolol is comparable with that reported in studies of 
assessing the ability of beta-blockers to limit myocardial similar patients lreated with other longer-acting inbavenous 
infarct size suggest that at least a moderate reduction in beta-blockers as well as in prior studies with esmolol in 
cumulative myocardial-specific enzyme release occurs when patients who were undergoing preopentive tracheal intuba- 
the drug is administered soon after the onset of chest pain. don or who developed rupraventricular tachycardia after 
Pooled results from many trials (6) employing early cardiac surgery (21-23, 3C33). 
intravenous beta-blockade for acute myocardial infarction Of parliodur importance in /hese pafienfs with compro- 
persistently demonstrate an approximately 15% reduction in misrd cardiac.function wns /he absence of uny significant 
mortality, ventricular fibrilla:ion and reinfarction during the change in left ventricrdarfilling pressure during fhe esmolol 
1st week after infarction. The two largest trials to date, infkrion, which lasted for up to 48 h IF&. 3j. Even those 
International Study of Infarct Survival (ISIS-I) (atenolol) (6) individuals who required a dose reduction or termination of 
and Metoprolol in Acute Myocardial Infarction (MIAMI) tbc infusion because of hypotension or low cardiac output 
(metoprolol) (27) suggest that the reduced mortality benefit had no appreciable rise in pulmonary capillary wedge pres- 
occurs primarily within the 1st day after myocardial infarc- sure. This finding is similar to results with other beta- 
lion. Thus. to achieve this improvement in initial postinfarc- blockers in patients with acute ischemia and normal or 
lion survival. early intervention appears necessary. abnormal ventricular function (31,34,35). Although there 
Risks of b&a-blockade in myocardial ischomia. The risks was a trend toward a reduction in cardiac index during the 
associated with immediate use of beta-blockers in patients esmolol infusion in this study, it failed to achieve statistical 
with myocardial infarction are not firmly established. In signiticance. Comparable effects on cardiac output and put- 
three recent large scale clinical trials (13-15~ of beta- monary capillary wedge pressure were obtained with esmo- 
blockade therapy after myocardial infarction. 47 to 77% of lol bv lskandrian et al. (361 in their studv of IO oatients with 
patients initially screeneh were not enrolled because of 
administrative considerations, continued use of beta- 
blockers or refusal to participate. and I8 to 28% of otherwise 
eligible patients were specifically excluded because of &so- 
lute or relative contraindications to beta-blockers. Thus. the 
apparent safety of intravenous beta-blockade dunng acute 
myocardial infarction has been confirmed only for carefully 
screened patients. Post hoc analysis of the majar beta- 
blockade intervention trials sw~ests that the vatients most 
a &an radionuclide-confirmed baselineieft ve&icular ejec- 
tion fraction of 27 + 2% (range 20 to 36%). 
Duration of action. The present study confirms previous 
observations of esmolol’s short duration of action in ani- 
mals. normal volunteers and patients with supraventriculsr 
tachycardia. perioperative hypertension or tachyarrhyth- 
miss or acute ischemia. Because intercurrent drug adminis- 
tration as well as an evolving clinical course over the 24 to 48 
h infusion oeriod mav have altered the hemodvnamic status 
likely to benefit from treatme~i are those al’highest risk: of individual patient& pre- and postesmalol hemodynarnic 
specifically. individuals suKeritx from left ventricular dvs- variables were occasionallv sliPhtlv different. However. 
function (28). Unfortunately, it h often clinically difficul;to 
identify palients who will have adverse reactions to beta- 
blockers. Cardiac failure, hypotension, bradycardia or AV 
block follows initiation of beta-blockade in approximately 2 
to 5% of carefully screened patients in the trials reported to 
date (4,9). These potential adverse side effects combined 
with the average 3 10 6 h biologic half-life of available 
beta-blockers frequently make clinicians wary of using such 
agents in patients with acute ischemia. especially if they 
have evidence of relative contraindications to beta-blockade 
(29). 
As demonstrated in this group of patients wilh moder- 
ately compromised left ventricular function, esmolol at 
relatively low doses WI to I50 &kg per minj induced a rapid 
decline of 10 to 15% in both heart rate and arterial systolic 
pressure. Further increases in the infusion rate rarely h;d 
additional negative chronotropic effect though systolic pres- 
. __ 
each patient had clear findings of rapid termination of drug 
effect by evidence of restoration toward baseline hemady- 
namics within IS to 30 min of esmolol termination. Erythro- 
cyle esterases are responsible for the hydrolysis of esmolol; 
thus, neither renal nor hepatic Row or function is central to 
metabolism of the drug (37). Consequently even in these 
patients with compromised left ventricular function. an 
extremely short biologic half-life was maintained. 
Clinical implications. As shown in this series of patients, 
esmolol can safely lower heart rate. arterial pressure and 
rate-pressure product in patients with acute myocardial 
ischemia or infarction and moderate left ventricular dysfunc- 
tion. This beneficial hemodynamic effect is titratable and 
appears to be achievable at a dose range of 50 to 200 fig&g 
per min without clinically significant changes in pulmonary 
capillary wedge pressure, cardiac index or AV conduction. 
Although similar hemodvnamic effects have been demon- 
sure continued lo decrease in a dose-dependent fashion. II 
was frequently possible to adjust concurrently administered 
:trated-with longer-act& beta-blockers in patients with a 
comparable degree of ischemic heart disease, esmolol’s 
intravenous nitroglycerin lo produce the desired degree of 
beta-blockade withow unduly compromising arterial pres- 
ultrashort duration of action permits greater Aexibiliiy in 
sure. This degree of decline in hear? rate and blood pressure 
adapting the desired degree of beta-blockade to the patient‘s 
evolving clinical status. The duration of undesirable re- 
soottses to beta-blockade during and after terrmnation of 
esmolol Infusion is mmimized by the drug‘s thort hinlogic 
half-life, and clinical stabdw I( easilv restored wth modA- 
cation of the dose (Fg. 4;. Funher&re. !he co-admmrtr;~- 
tion of nitroglycerin wa\ safely accomphshrd in nine pa- 
tients. Five patients did nut require any adjustment m the 
infusion rate of nitroglycerin. whereas four required dv?- 
ward titralion of the miroglycerin mfusion rate to mnmtain 
systolic arterial preswc Ml mm Hg. 
Combination of antiischemic therapies. Thromholytic 
therapy or percutaneous transluminal coronary ansioplasty. 
or both, may limit infarct size and reduce morbidity and 
mortalily in patients treated within hours of acute corooary 
occlusion. Zalewski et al. (38) demonstrated both a delayed 
development and a decreased masnttude of ST secment 
elevation during balloon dilation when patients undergoing 
coronary angioplasty were simultaneously treated with m- 
tracoronary propranolol. Several studies in dogs U9.401 
suggest hat there is enhanced salvage of ischemic myocar- 
dium or earlier functional recovery of infarcted tissue when 
beta-blockade is combined with early repetfttsion. Intrave- 
nous administration of beta-blockers oon after the onset of 
infarction in humans may have an additive salutary effect on 
myocardial infarct size when combined with thrombolysis or 
coronary angioplas:y (41). In addition. early treatment with 
beta-blockern may favorably alter mycardial oxygen dr- 
mattds. thereby slowing the progress of necrosis thmugh the 
myocardium and widening the therapeutic window for reper- 
fttsron. These concepts are currently being explored in large 
randomized clinical trials (42) with longer-acting bela- 
blockers. 
Because the sympathetic tone of patients in the first few 
hours after myocardial infarction may be different from that 
reported in the patients in this study. an imporwmt question 
for further study is the role of esmolol in the earliest stages 
of acute infarction. Use of an easily titratable. ultrashort- 
acting. cardioseleetive beta-blocker such as esmolol in nilu- 
ations where there are relative contraindications to heta- 
blofkade would broaden the clinical applicability of thtr 
important adjunctive pharmacotherapeutic option in the 
current era of repelfusion therapy for myocardial infarction. 
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